Concepedia

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie, Robert K. Stuart, Stephen A. Strickland, Donna E. Hogge, Scott R. Solomon, Dale L. Bixby,

The Lancet Haematology · 2021 · 211 citations · 20 references

DOI

Concepts

References

20

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations

, , +17

Age and acute myeloid leukemia

Frederick R. Appelbaum, Holly Gundacker, David R. Head et al. · Blood · 2006 · 1.3K citations · Full text

, , +12

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes et al. · Journal of Clinical Oncology · 2018 · 990 citations · Full text

, , +15

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Sabine Käyser, Konstanze Döhner, Jürgen Krauter et al. · Blood · 2010 · 485 citations

, , +11

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

Thomas Prébet, Steven D. Gore, Benjamin Esterni et al. · Journal of Clinical Oncology · 2011 · 480 citations · Full text

, , +16